Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51

Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51. Double Blind, Randomized, Controlled Phase 3 Study.

The objective is to demonstrate equivalence of three commercial IC51 batches in terms of geometric mean titers for anti-JEV neutralizing antibody

Main Inclusion Criteria:

• Male and female healthy adults aged at least 18 years, with written informed consent and either no childbearing potential or negative pregnancy test

Main Exclusion Criteria:

• History of immunodeficiency or immunosuppressive therapy,
• Known Human Immunodeficiency Virus (HIV); OR
• Drug addiction including alcohol dependence